System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Carlo Torti is an expert in Infectiology at Agostino Gemelli University Polyclinic (Italy). Carlo Torti has authored 533 publications, the most recent in 2026, and is an investigator in 10 clinical trials, 5 of them ongoing. SLR score: 1,562 (community average: 125). How the SLR is computed.

LeadR Profile

Carlo Torti Agostino Gemelli University Polyclinic Italy
1 562 ScienceLeadR Reputation 1562

Unlock

Register Login
Network Map

Infectiology

Subspecialties: Public Health - Pharmacy - Hepatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1997 - 2026
Source: PubMed

Magna Graecia University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 533

Citations

Citations: 15 721 1st author: 44 Last author: 94 Unique author: 0

Main journals

J Antimicrob Chemother 32
BMC Infect Dis 27
Clin Infect Dis 23
HIV Med 20
AIDS 19

Best Journals

Lancet 4
Nat Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Virological outcomes, resistance profile and viral evolution of lenacapavir-based regimens in heavily treatment-experienced people: data from the PRESTIGIO Registry.
PMID 42948967 — registries, drug therapy, capsid, viremia, therapeutics, plasma		J Antimicrob Chemother20260
Nutritional Status at Admission and Clinical Outcomes in Hospitalized Patients with COVID-19: Results from the MODIeCOSe in Italy Study.
PMID 42942949 — malnutrition, food, covid-19, anthropometry, nutritional status, intensive care units, prognosis, acute disease		Nutrients20260
Development and Internal Validation of a Clinical-Epidemiological Model for Active Pulmonary Tuberculosis Among Patients Already Evaluated for Suspected Disease in a Low-Incidence Hospital.
PMID 42906840 — research design, tuberculosis, pulmonary, safety, incidence, tuberculosis, communicable diseases		Int J Infect Dis20260
Risk factors for bloodstream infection caused by carbapenem-resistant Enterobacterales in patients with haematological malignancies: a systematic review and meta-analysis.
PMID 42885351 — diabetes mellitus, confidence intervals, epidemiology, fluoroquinolones, sepsis, risk factors, cephalosporins, carbapenems, infections		Epidemiol Rev20260
Trends in Hepatitis D Virus Prevalence Among HBsAg-Positive Individuals With and Without HIV in Italy: A Converging Epidemiology.
PMID 42834655 — hepatitis b surface antigens, hepatitis d, epidemiology, pharmaceutical preparations, hepatitis delta virus, liver, viruses, prevalence, infections, hepatitis		Liver Int20260

Clinical Studies 10

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 3 4
N/A 3
Phase 4 2
Phase 2 1

By status:

Completed 4
Active not recruiting 3
Not yet recruiting 1
Recruiting 1
Unknown 1

By type:

Interventional 8
Observational 2

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 0
multicentricup10 7

Main Topics

Cohort/Consortium Investigators 56

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Na ve Persons with HIV 1 (INNOVATE Study)
2025-521918-26-00 — hiv-1, tenofovir, safety, hiv, emtricitabine, therapeutics, hiv infections, infections		Phase 2Active not recruiting2026
Early DOlutegravir LAmivudine Switching after virological suppression (EDOLAS Study)
2024-518909-18-00 — hiv-1, safety, pharmaceutical preparations, lamivudine, hiv, rna, dolutegravir		Phase 3Active not recruiting2021
PipEracillin Tazobactam versus mERoPENem for treatment of bloodstream infections caused by cephalosporin resistant Enterobacteriaceae a non inferiority randomized controlled trial (PETERPEN)
2024-518583-13-00 — bacteremia, piperacillin, tazobactam drug combination, piperacillin, tazobactam, sepsis, meropenem, cephalosporins, therapeutics, enterobacteriaceae, infections		Phase 4Recruiting2025
Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem Resistant Enterobacterales
NCT07160569 — genes, enterobacteriaceae infections, whole genome sequencing, genome, carbapenem-resistant enterobacteriaceae, communicable diseases, carbapenems, enterobacteriaceae, infections		N/ANot yet recruiting2025
Evaluation of T cell Responses After Vaccination With the Attenuated Tetravalent Dengue Vaccine (Takeda)
NCT07158190 — cells, vaccines, lymphocytes, vaccination, viruses, dengue, t-lymphocytes, dengue vaccines, infections		N/AActive not recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS